Back to News
Market Impact: 0.35
AbbVIe's Zumilokibart Meets Phase 2 Goal In Atopic Dermatitis Study
Source: Nasdaq
Healthcare & Biotech
AbbVie reported positive Phase 2 APEX Part B results for zumilokibart in adults with moderate-to-severe atopic dermatitis. The favorable mid-stage clinical readout supports further development of the dermatology treatment candidate and could bolster AbbVie's immunology pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
ABBV0.72
More News
- AbbVie’s zumilokibart meets phase 2 atopic dermatitis endpoint
- AbbVie presents phase 1 data for obesity drug ABBV-295
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
- Some Oura IPO Investors Were Said to Push Back Citing Valuation
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Eli Lilly Q4 2025 Earnings: Revenue Surges 43% as Mounjaro and Zepbound Dominate the GLP-1 Market
- Investment Research Software Costs: A 2026 Budget Framework